Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company, announced that its CEO and Chairman, Dr. Vuong Trieu, will present at the OTCQB Virtual Investor Conference on August 6, 2026, at 2:30 p.m. ET. The presentation will include a live question-and-answer session, providing investors with direct access to the company's leadership.
The company plans to highlight several key developments, including the advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort. This milestone represents a critical step in the clinical evaluation of the therapy, which is being developed for cancer treatment. Additionally, Oncotelic has expanded its European clinical sites, broadening the reach of its trials and potentially accelerating patient recruitment and data collection.
Oncotelic will also discuss the validation of its Deciparticle platform through peer-reviewed publications. The Deciparticle technology is a proprietary drug delivery system designed to enhance the efficacy and safety of therapeutic agents. The company's scalable cGMP manufacturing capabilities will be a focal point, underscoring its ability to produce clinical-grade materials efficiently and in compliance with regulatory standards.
Further, the presentation will cover Oncotelic's continued development of AI-driven drug discovery, robotics, and nanomedicine platforms. These initiatives reflect the company's commitment to integrating cutting-edge technology into its research and development processes, potentially reducing timelines and improving success rates in drug development.
According to the press release, the OTCQB Virtual Investor Conference offers a unique opportunity for investors to engage with company executives and gain insights into Oncotelic's strategic direction. The company's participation highlights its dedication to transparency and shareholder communication.
Oncotelic Therapeutics focuses on developing innovative therapies for cancer and other serious diseases through precision medicine, RNA therapeutics, artificial intelligence, and advanced nanomedicine delivery technologies. Its portfolio includes clinical-stage oncology assets, the proprietary Deciparticle drug delivery technology, AI-enabled drug discovery platforms, and scalable GMP manufacturing capabilities. These assets are designed to accelerate development while improving patient outcomes.
The announcement comes as the biotech sector continues to see increased interest in AI and nanomedicine applications, which are viewed as potential game-changers in personalized medicine. Oncotelic's progress in these areas could position it as a leader in the integration of these technologies into clinical practice.
For more information about Oncotelic Therapeutics and its latest updates, visit the company's newsroom at https://nnw.fm/OTLC. The full press release is available at https://nnw.fm/fGHUt.
